Literature DB >> 7560857

Peptic ulcer and its course in cirrhosis: an endoscopic and clinical prospective study.

S Siringo1, A K Burroughs, L Bolondi, A Muia, G Di Febo, M Miglioli, G Cavalli, L Barbara.   

Abstract

The epidemiological and clinical characteristics of peptic ulcer were studied in 324 of 368 consecutive patients with cirrhosis of the liver during a mean period of 1.2 (+/- 0.61) years. Peptic ulcer prevalence rates in patients with cirrhosis were as follows: point prevalence 11.7%, period prevalence 15.1%, and life-time prevalence 24.2%. The annual incidence rate observed in 140 patients with cirrhosis undergoing endoscopic follow up was 4.3%. Ulcers were asymptomatic in more than 70% of patients. The peptic ulcer complication rate at entry was 20% in the whole group and 40% in those who had not a previous diagnosis of peptic ulcer when admitted to the study. Peptic ulcer was more frequent among HBsAg+ cirrhotics (p = 0.05). Patients with more severely decompensated cirrhosis also had a higher frequency of asymptomatic ulcers (p = 0.04), gastric ulcers (p = 0.01) and asymptomatic gastric ulcers (p = 0.005). After diagnosis, during endoscopic follow up, gastric ulcer in patients with cirrhosis tended to heal slowly and recurred with higher frequency than in controls without cirrhosis (p = 0.04). Seventy-nine per cent of peptic ulcer recurrences were asymptomatic in patients with cirrhosis. There were no complications during the follow-up period: this could be due to the regular timing of endoscopy, which permitted early detection and treatment of the recurrences, thus preventing further complications.

Entities:  

Mesh:

Year:  1995        PMID: 7560857     DOI: 10.1016/0168-8278(95)80219-3

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  22 in total

1.  Helicobacter pylori infection is not associated with subclinical hepatic encephalopathy in stable cirrhotic patients.

Authors:  I A Scotiniotis; M R Lucey; D C Metz
Journal:  Dig Dis Sci       Date:  2001-12       Impact factor: 3.199

Review 2.  Non-variceal gastrointestinal bleeding in patients with liver cirrhosis: a review.

Authors:  M Kalafateli; C K Triantos; V Nikolopoulou; A Burroughs
Journal:  Dig Dis Sci       Date:  2012-06-04       Impact factor: 3.199

3.  Distinctive aspects of peptic ulcer disease, Dieulafoy's lesion, and Mallory-Weiss syndrome in patients with advanced alcoholic liver disease or cirrhosis.

Authors:  Borko Nojkov; Mitchell S Cappell
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  [Personnel calculation in health care: intensive care and intermediate care units].

Authors:  W Plücker
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-10-15       Impact factor: 0.840

Review 5.  Dose adjustment in patients with liver disease.

Authors:  Fabiola Delcò; Lydia Tchambaz; Raymond Schlienger; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 6.  Avoiding pitfalls: what an endoscopist should know in liver transplantation--part 1.

Authors:  Sharad Sharma; Ahmet Gurakar; Nicolas Jabbour
Journal:  Dig Dis Sci       Date:  2007-11-09       Impact factor: 3.199

7.  Association between Helicobacter pylori infection and cirrhosis in patients with chronic hepatitis C virus.

Authors:  Dulciene Maria Magalhães Queiroz; Andreia Maria Camargos Rocha; Gifone Aguiar Rocha; Sarah Maria Singulano Cinque; Adriana Gonçalves Oliveira; Alicia Godoy; Hugo Tanno
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

8.  Predictive factors for gastroduodenal toxicity based on endoscopy following radiotherapy in patients with hepatocellular carcinoma.

Authors:  H Yoon; D Oh; H C Park; S W Kang; Y Han; D H Lim; S W Paik
Journal:  Strahlenther Onkol       Date:  2013-05-25       Impact factor: 3.621

9.  High prevalence of Helicobacter pylori in liver cirrhosis: relationship with clinical and endoscopic features and the risk of peptic ulcer.

Authors:  S Siringo; D Vaira; M Menegatti; F Piscaglia; S Sofia; M Gaetani; M Miglioli; R Corinaldesi; L Bolondi
Journal:  Dig Dis Sci       Date:  1997-10       Impact factor: 3.199

10.  Impact of Helicobacter pylori eradication on refractory thrombocytopenia in patients with chronic HCV awaiting antiviral therapy.

Authors:  A S Hanafy; A T El Hawary; E F Hamed; A M Hassaneen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-05-14       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.